Dividend Policy - The company plans to distribute a cash dividend of 0.40 CNY per 10 shares, totaling approximately 20,030,613.08 CNY, which represents 26.66% of the net profit attributable to shareholders for the first half of 2025 [2]. Product Performance - The revenue from ultra-high molecular weight polyethylene fiber reached 88.06 million CNY in the first half of 2025, marking a year-on-year growth of 2.61%, with a gross margin of 27.15%, up by 12.98% [12]. - The company has improved the first-class rate of ultra-high molecular weight polyethylene fiber products, enhancing customer trust and market expansion [2]. Market Expansion - The company is focusing on the domestic and international markets, with a strategy to provide customized services and maintain long-term partnerships to boost market share [10]. - The demand for ultra-high molecular weight polyethylene fiber in the civilian and military sectors is steadily increasing, with significant growth expected in humanoid robotics applications [4]. Research and Development - The company is actively developing high-performance nylon fibers with applications in robotics, including features like flame retardancy, UV resistance, and antibacterial properties [9]. - Continuous innovation in product specifications and production processes is aimed at meeting the evolving needs of the robotics industry [13]. Supply Chain Management - The company has established stable relationships with suppliers to optimize procurement costs and ensure the quality and stability of raw materials [6]. - A green procurement approach is being adopted to reduce the carbon footprint and enhance product sustainability [6]. Strategic Focus - The company's strategic framework emphasizes traditional woolen clothing as the foundation while expanding into new material fibers as a growth driver [11].

Dividend Policy and Shareholder Returns - The company plans to distribute a cash dividend of 4.5 CNY per 10 shares for 2024, representing 99.74% of the net profit for that year [1][2] - The rationale for the high dividend includes regulatory guidance on cash dividends, strong cash reserves, low debt levels, and positive feedback from institutional investors [2][3] - The dividend strategy aims to enhance the stability, sustainability, and predictability of cash dividends, making the stock more attractive to investors [2][3] Market Performance and Sales Outlook - Cement sales in July and August were affected by seasonal factors, with demand remaining stable year-on-year but declining compared to June [3][4] - The company aims to achieve a sales target of over 16.3 million tons of cement and a net profit of over 530 million CNY for 2025 [4] - The first half of 2025 saw a 10.90% increase in "cement + clinker" sales, totaling 8.11 million tons [4] Production Policies and Market Conditions - The staggered production policy for 2025 includes 95 days of shutdown in Guangdong, 160 days in Guangxi, and 170 days in Fujian, effectively reducing supply and supporting prices [5][6] - Recent weather conditions have delayed price increases in the Pearl River Delta, but prices are expected to stabilize as the sales season begins in September [6] Investment Strategy and Securities - The company has approved a securities investment budget of 1.3 billion CNY for 2025, focusing on low-risk investments such as government bonds and quantitative products [7][8] - The investment strategy emphasizes risk control and stability, with a commitment to maintaining a reasonable investment scale and avoiding significant fluctuations in performance [8]

Group 1: Company Overview and Strategy - The company expressed gratitude to institutional investors and introduced its basic situation, development strategy, and the 2025 semi-annual report [2] - The company emphasizes compliance with commitment letters and regulations regarding information disclosure [2] Group 2: Project Updates - The high-end valve intelligent manufacturing project initiated in Q2 2024 has completed civil engineering and is moving into equipment installation and debugging, expected to enter trial production by the end of 2025 [2] - New production capacity will cover various valve types including butterfly valves, ball valves, diaphragm valves, and instrument valves [6][7] Group 3: Nuclear Power Orders and Market Dynamics - In May 2025, five projects with a total of 10 new nuclear power units were approved, with procurement bidding expected to start in the second half of 2025 [3] - There has been a slight decline in nuclear power orders compared to the same period last year due to differences in bidding progress and long-cycle processes [4][5] - The company's product pricing follows a cost-plus method, benefiting from long-term production and delivery experience [8] Group 4: Financial Performance and Future Outlook - The company's nuclear valve product gross margin is currently stable, with expectations to maintain this stability unless there are significant changes in the business model or market competition [9] - The company aims to expand its export scale and international presence, focusing on core areas such as oil refining and gas extraction [10] Group 5: Challenges and Responses - The steel metallurgy sector has seen a decline, leading to reduced market demand for valve products; the company is enhancing product R&D and promoting cost-reduction measures [13] - The company is committed to increasing its market share in the energy and chemical sectors despite intensified competition [13]

Group 1: Investor Relations Activities - The investor relations activities included roadshow events and telephone surveys [2] - Participating institutions included Daiwa Securities, Huatai Securities, GF Securities, CITIC Securities Asset Management, Shanghai Chongshan Investment, Guoshou Anbao Fund, and Yangtze River Asset Management [2] - The activities took place from August 26 to August 27, 2025, at the Board Secretary's office and two hotels in Shanghai [2] Group 2: Company Overview - The company provided an overview of its production and operational status for the first half of 2025 [2] - Future development trends were also discussed during the investor relations activities [2] - The meeting was attended by the Vice President and Board Secretary, Mr. Zhang Qiqiang, and Securities Affairs Representative, Ms. Chen Mingdi [2]

Financial Performance - The company achieved operating revenue of 210 million yuan, a year-on-year increase of 9.45% [2] - Operating income from the petroleum and petrochemical sector was 101.45 million yuan, up 7.95%, accounting for 48.28% of total revenue [3] - Revenue from the coal and electricity sector grew significantly by 50.73% to 24.90 million yuan, representing 11.85% of total revenue [3] - The overall gross profit margin decreased to 35.05%, down 3.5 percentage points from the previous year [5] Cost Structure - Total operating costs amounted to 136 million yuan, an increase of 15.69% year-on-year [5] - Employee compensation accounted for 72.63% of total costs, totaling 99.12 million yuan, with a year-on-year increase of 11.25% [5] - Other expenses, including travel, rent, and external services, totaled 37.37 million yuan, making up 27.37% of total costs, with a significant increase of 29.36% [5] R&D and Innovation - R&D expenses reached 43.63 million yuan, a 77.50% increase year-on-year, reflecting a strong focus on innovation [6] - The company plans to enhance R&D investment in key areas such as ERP, cloud platforms, and AI applications [14] Strategic Developments - The company is focusing on deepening relationships with six traditional strategic clients while expanding to new clients [9] - Significant progress has been made in the financial sector, with successful implementations of financial shared platforms and treasury management systems [10][17] - The company aims to leverage AI and digital transformation to enhance service offerings and operational efficiency [19] Future Outlook - The second half of the year is critical for project delivery and revenue recognition, with expectations for increased contract signings and cash flow [7] - The company is optimistic about achieving its 2025 operational goals, focusing on market expansion and technological innovation [16]

Group 1: Company Performance - In the first half of 2025, the company achieved a revenue of 26.985 billion RMB, a year-on-year increase of 12.82% [1] - The net profit attributable to shareholders was 856 million RMB, up 3.88% year-on-year [1] - Revenue from consumer battery business reached 13.890 billion RMB, growing by 5.22% [1] - Revenue from electric vehicle battery business was 7.604 billion RMB, with a growth of 22.63% [1] - Revenue from energy storage systems reached 1.004 billion RMB, marking a significant increase of 68.85% [1] - Other business revenue was 4.486 billion RMB, up 14.39% [1] - The company plans to distribute a cash dividend of 0.60 RMB per 10 shares, totaling approximately 110.30 million RMB [1] Group 2: Battery Shipment and Financials - The total shipment of power batteries in the first half of 2025 was 16.08 GWh, reflecting a substantial year-on-year growth of 93.04% [2] - The increase in financial expenses was primarily due to reduced foreign exchange gains, with losses attributed to fluctuations in the Indian and US dollar exchange rates [2] Group 3: Product Development and Market Trends - The first-generation semi-solid battery has been developed with an energy density exceeding 300 Wh/kg; the second-generation samples are undergoing pilot testing [3] - The ratio of ternary to lithium iron phosphate battery shipments in the first half of 2025 was 2:8, consistent with industry trends [3] - Emerging markets for consumer batteries include gimbal products, service robots, and VR/AR glasses, with notable sales growth [4] Group 4: IPO and New Product Launches - The company submitted its A1 prospectus to the Hong Kong Stock Exchange on July 30, 2025, with the IPO subject to various regulatory approvals [5] - A new ultra-fast charging battery product matrix was launched in May 2025, featuring a charging capability of 12C and a recharge time of 5 minutes [6] - The world's first 1,400A flash charging battery, capable of providing 450 kilometers of range in 5 minutes, was introduced [6]

Group 1: Company Performance and Strategy - In the first half of 2025, the "Starlink Plan" accounted for nearly 30% of total revenue, with significant improvements in profit and sales profit margins for both Starlink semi-trailers and liquid tankers [3][4] - The production of Starlink semi-trailers increased by 15% in terms of LTP group output [3] - The company is actively responding to national "anti-involution" policies, marking the beginning of its third entrepreneurial phase focused on structural changes in semi-trailer production [3][4] Group 2: North American Market Insights - In the first half of 2025, North American semi-trailer production was 108,800 units, a year-on-year decline of 24.3%, indicating a severely weak demand [4] - Despite challenges, the company sold 7,888 units in North America, maintaining profitability amid tariff impacts and demand downturns [4][5] - The company anticipates a potential weak recovery in the North American semi-trailer market in the second half of 2025, driven by easing tariff conditions and seasonal demand [4] Group 3: Product Development and Innovation - The company is accelerating the development of its "pure electric head trailer" product line and establishing operational support bases for these vehicles [6][8] - The "Hannover Plan" aims to enhance the product iteration and commercialization process for electric trailers, with a focus on seamless integration from R&D to market [8] - The company plans to participate in the formulation of national standards for electric trailers, with key events scheduled for 2024 and 2025 [8] Group 4: Infrastructure and Market Expansion - The company is establishing a super center in Luzhou to support multiple vehicle types, enhancing its operational efficiency and market reach in the southwest region [7] - The EV·DTB business is positioned to benefit from major infrastructure projects like the Yarlung Zangbo River hydropower project, which aligns with national development plans [5][6]

证券代码：002916 证券简称：深南电路 深南电路股份有限公司投资者关系活动记录表 | 编号：2025-27 | | --- | | 投资者关系 | √特定对象调研 □分析师会议 □现场参观 | | --- | --- | | 活动类别 | □媒体采访 □业绩说明会 □新闻发布会 | | | □路演活动 □其他 （ ） | | | 国泰海通、华创证券、华泰证券、嘉实基金、泉果基金、上海证券、施罗德基金、易方达基 | | | 金、永赢基金、招商证券、中国国际金融、银华基金、诺德基金、安信基金、长城基金、华 | | | 夏基金、恒越基金、创金合信基金、博时基金、九泰基金、国金基金、汇添富基金、泰信基 | | | 金、天弘基金、金元顺安基金、安联基金、国融基金、国投瑞银基金、浦银安盛基金、长盛 | | | 基金、申万菱信基金、农银汇理基金、诺安基金、财通基金、方正富邦基金、摩根士丹利基 | | | 金、摩根证券投资信托、路博迈（亚洲）、广东君心盈泰投资、上海保银私募基金、上海聆 | | | 泽投资、淡水泉(北京)投资、耕霁(上海)投资、北京市星石投资、北京泽铭投资、江苏瑞华 | | | 投资、上海雷钧私募基金、湖 ...

Group 1: Financial Performance - The company's operating revenue for the first half of 2025 was ¥59,961,774.27, representing a year-on-year increase of 68.77% [3] - The net profit attributable to shareholders decreased by 17.71% to ¥20,797,156.80 [3] - The net profit after deducting non-recurring gains and losses was -¥12,784,853.85, showing a year-on-year increase of 40.04% [3] - As of the end of the reporting period, total assets amounted to ¥6,912,395,737.39, with net assets attributable to shareholders at ¥5,918,534,037.40 [3] Group 2: Dividend Policy - The 2024 dividend plan is to distribute ¥2 per 10 shares, with a total cash dividend of ¥8 per 10 shares for 2025 [4] - The average annual net profit attributable to shareholders over the past three years was ¥5.284 billion, with cumulative cash dividends of ¥706.4 million, resulting in a payout ratio of 133.69% [4] - The company aims to enhance the stability and predictability of cash dividends while increasing the average payout ratio [4] Group 3: Vaccine Industry Insights - The global human vaccine market grew from $27.7 billion in 2017 to $46 billion in 2021, with a compound annual growth rate (CAGR) of 13.5%, projected to reach $83.1 billion by 2025 and exceed $131 billion by 2030 [4] - In China, the overall vaccination rate for influenza vaccines is approximately 3%, significantly lower than the rates in developed countries [5] - The CDC reported that the vaccination rates for the 2023-2024 flu season in the U.S. were 55.4% for ages 6 months to 17 years, 44.9% for adults, and 69.7% for seniors aged 65 and above [5] Group 4: Market Strategy and Future Growth - The company has established a sales network covering over 2,500 disease control centers across more than 30 provinces, achieving over 70% coverage [5] - To improve accessibility and market competitiveness, the company adjusted the price of its quadrivalent influenza vaccine starting June 5, 2024 [6] - Future growth points include the development of rabies and tetanus vaccines, with the company also advancing clinical trials for new products like mRNA vaccines [6]

Financial Performance - The company's operating revenue for the first half of 2025 was 1.798 billion CNY, an increase of 8.8% compared to the same period last year [3] - The net profit attributable to shareholders was 516 million CNY, up 17.19% year-on-year [3] - The net profit after deducting non-recurring gains and losses was 484 million CNY, reflecting a growth of 33.41% [3] - Total assets at the end of the reporting period amounted to 15.535 billion CNY, with net assets attributable to shareholders at 12.013 billion CNY [3] Plasma Collection and Business Development - The company collected a total of 803.66 tons of plasma in the first half of 2025, marking a 5.23% increase year-on-year [3] - New plasma collection stations were established, including one in Fengdu County, Chongqing, which has begun operations [3] - The company is actively enhancing its plasma collection capabilities through quality management and staff training [3] R&D and Product Pipeline - The company is advancing its innovative drug and biosimilar development, with several products in various stages of clinical trials [4][5][6][7] - The restructured Exendin-4-FC injection for type 2 diabetes has completed Phase I/II trials and is preparing for Phase III [4] - Rituximab injection and other biosimilars have completed Phase III trials and are awaiting market approval [5][6][7] Market Strategy and International Expansion - The company achieved sales revenue of 58.8958 million CNY from Bevacizumab in the first half of 2025 and is pursuing international market entry [7] - The company has initiated drug registration processes for Bevacizumab in countries such as Turkey, Brazil, and Pakistan [7] Dividend Policy - The company has distributed a total of 5.34 billion CNY in dividends since its listing, with a proposed cash dividend of 913.73 million CNY for the first half of 2025 [8][9] - The dividend payout ratio for the first half of 2025 is 177.13% of the net profit attributable to shareholders [9] Industry Trends and Challenges - The blood products industry is experiencing consolidation, with the top five companies holding 80-85% of the market share globally [10][11] - The company is actively seeking merger and acquisition opportunities to enhance its core competitiveness and expand its business scope [11] - The pricing pressure on traditional blood products is increasing due to rising plasma collection and competition from recombinant products [12] Vaccine Market Insights - The global human vaccine market is projected to grow from 27.7 billion USD in 2017 to 83.1 billion USD by 2025, with a compound annual growth rate of 13.5% [13] - The company is focusing on increasing public awareness and vaccination rates, particularly for influenza vaccines [13][14] - The company has adjusted the pricing of its influenza vaccines to enhance market competitiveness [14]